title: Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study.
abstract: BACKGROUND
  Gemcitabine is a pro-drug that has to be phosphorylated to gemcitabine-triphosphate in order to exhibit its antineoplastic activity. This reaction involves the enzyme deoxycytidine kinase which is saturated at plasma concentrations following standard 30-min infusions. Pharmacological studies indicate that prolonged administration of gemcitabine might result in higher intracellular concentrations of active metabolites. This phase I trial was therefore initiated to determine the optimal dose of gemcitabine administered over 4 h in patients with advanced solid tumors.
  
  
  METHODS
  Patients were treated with gemcitabine as 4 h-infusion on day 1, 8 and 15 in 4 week intervals. The starting dose was 350 mg/m(2). Doses were escalated in 50 mg/m(2) increments.
  
  
  RESULTS
  Twenty-one patients were treated at doses ranging from 350 to 450 mg/m(2). The maximum tolerated dose was 400 mg/m(2) with neutropenia, thrombocytopenia, stomatitis and elevation of liver enzymes being dose limiting toxicities (DLTs). Hematologic and nonhematological toxicities were generally mild to moderate. Most common side effects were myelosuppression, nausea, elevation of liver enzymes and asthenia. Objective responses were noted in patients with hepatocellular carcinoma and cholangio-carcinoma.
  
  
  CONCLUSIONS
  In this phase I study of gemcitabine as 4h-infusion, DLTs were neutropenia, thrombocytopenia, stomatitis and elevation of liver enzymes. The recommended dose for phase II studies is 400 mg/m(2).
authors.affiliation: Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie, Charité Campus Mitte, Humboldt Universität zu Berlin, 10117 Berlin, Germany. peter.schmid@charite.de
authors.forename: Peter
authors.initials: P
authors.lastname: Schmid
authors.forename: Marcus
authors.initials: M
authors.lastname: Schweigert
authors.forename: Thomas
authors.initials: T
authors.lastname: Beinert
authors.forename: Bernd
authors.initials: B
authors.lastname: Flath
authors.forename: Orhan
authors.initials: O
authors.lastname: Sezer
authors.forename: Kurt
authors.initials: K
authors.lastname: Possinger
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000145:classification / Q000188:drug therapy*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine
references.citation: Cancer Chemother Pharmacol. 1991;27(4):258-62
references.pmid: 1998982
references.citation: J Clin Oncol. 1991 Mar;9(3):491-8
references.pmid: 1999720
references.citation: Cancer Chemother Pharmacol. 1996;38(4):335-42
references.pmid: 8674156
references.citation: Semin Oncol. 1995 Aug;22(4 Suppl 11):3-10
references.pmid: 7481842
references.citation: Invest New Drugs. 1997;15(4):331-41
references.pmid: 9547676
references.citation: J Clin Oncol. 1994 Aug;12(8):1527-31
references.pmid: 8040662
references.citation: Anticancer Drugs. 1999 Jul;10(6):525-31
references.pmid: 10885899
references.citation: Invest New Drugs. 1998-1999;16(3):275-8
references.pmid: 10360609
references.citation: Semin Oncol. 1995 Aug;22(4 Suppl 11):19-25
references.pmid: 7481840
references.citation: Anticancer Drugs. 1995 Dec;6 Suppl 6:27-32
references.pmid: 8718422
references.citation: Ann Oncol. 1998 Sep;9(9):1003-8
references.pmid: 9818075
references.citation: Invest New Drugs. 1997;15(2):115-21
references.pmid: 9220290
references.citation: Anticancer Drugs. 2001 Oct;12(9):713-7
references.pmid: 11593051
references.citation: Anticancer Drugs. 1999 Aug;10(7):625-31
references.pmid: 10507311
references.citation: Cancer Res. 1990 Nov 1;50(21):6823-6
references.pmid: 2208147
references.citation: Semin Oncol. 1995 Aug;22(4 Suppl 11):11-8
references.pmid: 7481839
references.citation: Ann Oncol. 2000 Oct;11(10):1309-11
references.pmid: 11106121
references.citation: Cancer Chemother Pharmacol. 2002 Jul;50(1):80-3
references.pmid: 12111116